RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants. The US Food and Drug ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.